Forte Biosciences Statistics
Share Statistics
Forte Biosciences has 6.58M
shares outstanding. The number of shares has increased by -82.46%
in one year.
| Shares Outstanding | 6.58M |
| Shares Change (YoY) | -82.46% |
| Shares Change (QoQ) | 337.32% |
| Owned by Institutions (%) | 41.38% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 770 |
| FTD / Avg. Volume | 2.3% |
Short Selling Information
The latest short interest is 104.76K, so 1.64% of the outstanding
shares have been sold short.
| Short Interest | 104.76K |
| Short % of Shares Out | 1.64% |
| Short % of Float | 1.66% |
| Short Ratio (days to cover) | 5.09 |
Valuation Ratios
The PE ratio is -1.87 and the forward
PE ratio is -2.64.
Forte Biosciences's PEG ratio is
0.04.
| PE Ratio | -1.87 |
| Forward PE | -2.64 |
| PS Ratio | 0 |
| Forward PS | 2.2 |
| PB Ratio | 1.26 |
| P/FCF Ratio | -2.15 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Forte Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.76,
with a Debt / Equity ratio of 0.
| Current Ratio | 6.76 |
| Quick Ratio | 6.76 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,534,142.86 |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -59.73% in the
last 52 weeks. The beta is 2.86, so Forte Biosciences's
price volatility has been higher than the market average.
| Beta | 2.86 |
| 52-Week Price Change | -59.73% |
| 50-Day Moving Average | 7.14 |
| 200-Day Moving Average | 10.67 |
| Relative Strength Index (RSI) | 51.52 |
| Average Volume (20 Days) | 33,509 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -36.6M |
| Net Income | -35.48M |
| EBITDA | -35.44M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -12.17 |
Full Income StatementBalance Sheet
The company has 22.24M in cash and 0 in
debt, giving a net cash position of 22.24M.
| Cash & Cash Equivalents | 22.24M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -154M |
| Total Assets | 61.56M |
| Working Capital | 52.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -30.75M
and capital expenditures -37K, giving a free cash flow of -30.78M.
| Operating Cash Flow | -30.75M |
| Capital Expenditures | -37K |
| Free Cash Flow | -30.78M |
| FCF Per Share | -10.56 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
